134 related articles for article (PubMed ID: 20205051)
1. HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases.
Marconi P; Manservigi R; Epstein AL
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):169-83. PubMed ID: 20205051
[TBL] [Abstract][Full Text] [Related]
2. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
3. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.
Saeki Y; Fraefel C; Ichikawa T; Breakefield XO; Chiocca EA
Mol Ther; 2001 Apr; 3(4):591-601. PubMed ID: 11319922
[TBL] [Abstract][Full Text] [Related]
4. HSV-1-based amplicon vectors: design and applications.
Epstein AL
Gene Ther; 2005 Oct; 12 Suppl 1():S154-8. PubMed ID: 16231049
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
7. [Herpes simplex type-1 virus-based vectors for gene therapy].
Ichikawa T; Saeki Y; Tamiya T; Chiocca EA; Ohmoto T
Nihon Rinsho; 2000 Apr; 58(4):822-7. PubMed ID: 10774201
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus type 1-based amplicon vectors for fundamental research in neurosciences and gene therapy of neurological diseases.
Jerusalinsky D; Baez MV; Epstein AL
J Physiol Paris; 2012 Jan; 106(1-2):2-11. PubMed ID: 22108428
[TBL] [Abstract][Full Text] [Related]
9. Replication-defective genomic HSV gene therapy vectors: design, production and CNS applications.
Burton EA; Fink DJ; Glorioso JC
Curr Opin Mol Ther; 2005 Aug; 7(4):326-36. PubMed ID: 16121698
[TBL] [Abstract][Full Text] [Related]
10. Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration.
Sia KC; Wang GY; Ho IA; Khor HY; Miao L; Hui KM; Lam PY
J Virol Methods; 2007 Feb; 139(2):166-74. PubMed ID: 17074404
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
12. HSV trafficking and development of gene therapy vectors with applications in the nervous system.
Frampton AR; Goins WF; Nakano K; Burton EA; Glorioso JC
Gene Ther; 2005 Jun; 12(11):891-901. PubMed ID: 15908995
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus type 1 (HSV-1)-derived amplicon vectors for gene transfer and gene therapy.
Fraefel C; Marconi P; Epstein AL
Methods Mol Biol; 2015; 1254():295-316. PubMed ID: 25431073
[TBL] [Abstract][Full Text] [Related]
15. Multiple applications for replication-defective herpes simplex virus vectors.
Burton EA; Wechuck JB; Wendell SK; Goins WF; Fink DJ; Glorioso JC
Stem Cells; 2001; 19(5):358-77. PubMed ID: 11553845
[TBL] [Abstract][Full Text] [Related]
16. Long-term persistence of defective HSV-1 vectors in the rat brain is demonstrated by reactivation of vector gene expression.
Starr PA; Lim F; Grant FD; Trask L; Lang P; Yu L; Geller AI
Gene Ther; 1996 Jul; 3(7):615-23. PubMed ID: 8818649
[TBL] [Abstract][Full Text] [Related]
17. Efficient and non-toxic gene transfer to cardiomyocytes using novel generation amplicon vectors derived from HSV-1.
Ferrera R; Cuchet D; Zaupa C; Revol-Guyot V; Ovize M; Epstein AL
J Mol Cell Cardiol; 2005 Jan; 38(1):219-23. PubMed ID: 15623439
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus type 1 (HSV-1)-derived amplicon vectors.
Melendez ME; Fraefel C; Epstein AL
Methods Mol Biol; 2014; 1144():81-98. PubMed ID: 24671678
[TBL] [Abstract][Full Text] [Related]
19. Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders.
Geller AI; Yu L; Wang Y; Fraefel C
Exp Neurol; 1997 Mar; 144(1):98-102. PubMed ID: 9126158
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
